Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DinutuximabProcedure: FDG-Positron Emission TomographyRadiation: Iobenguane I-123Drug: IrinotecanDrug: IsotretinoinProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanBiological: SargramostimDrug: Temozolomide
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT04385277
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-07-19
- Target Recruit Count
- 388
- Registration Number
- NCT04358354
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-08-24
- Target Recruit Count
- 136
- Registration Number
- NCT04358341
- Locations
- 🇨🇳
Jian Xiao, Guangzhou, Guangdong, China
Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-08-28
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 54
- Registration Number
- NCT04361708
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
- Conditions
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 550
- Registration Number
- NCT04342910
- Locations
- 🇨🇳
Affiliated Hospital, Academy of Military Medical Sciences, Beijing, China
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 352
- Registration Number
- NCT04340141
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Henry Ford Health Providence Novi Hospital, Novi, Michigan, United States
A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04337879
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shengyang, Liaoning, China
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Malignant Uterine NeoplasmMetastatic Appendix CarcinomaMetastatic Colorectal CarcinomaMetastatic Gastric CarcinomaMetastatic Malignant Neoplasm in the PeritoneumMetastatic Malignant Solid NeoplasmMetastatic Ovarian Carcinoma
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT04329494
- Locations
- 🇺🇸
Northwell Health Cancer Institute at Huntington, Greenlawn, New York, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: CarboplatinProcedure: Computed TomographyDrug: CyclophosphamideDrug: DoxorubicinDrug: EtoposideDrug: IfosfamideDrug: IrinotecanProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyRadiation: Radiation TherapyProcedure: Surgical ProcedureProcedure: Transabdominal UltrasoundDrug: TopotecanDrug: VincristineProcedure: X-Ray Imaging
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT04322318
- Locations
- 🇺🇸
Tufts Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04299880
- Locations
- 🇯🇵
Kyorin University Hospital, Tokyo, Japan
🇺🇸Maine Center for Cancer Medicine, Scarborough, Maine, United States
🇺🇸Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.